The meta-analysis suggests that a single dose of intravenous esketamine during delivery or caesarean section may reduce the risk of postpartum depression by more than 50% in the first 6 weeks. However, the long-term safety and efficacy of the drug are still unclear. Preliminary studies show a significant reduction in PPD incidence at 1 and 6 weeks after delivery with esketamine. Safety concerns, potential addiction, and the effect on babies need to be assessed. More studies are needed to determine the effectiveness of esketamine for all women with PPD. Overall, more treatment options for PPD are welcomed but require further investigation.
Source link
Esketamine Linked to Reduced Postpartum Depression Risk
